Mesenchymal Stem Cell Exosome Treatment of Congenital Myasthenic Syndrome
The Foundation for Orthopaedics and Regenerative Medicine
Summary
Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.
Description
Single Arm non-controlled study. Patients are prospectively evaluated then treated. Outcomes are tracked after treatment.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patients will need a diagnosis of Congenital Myasthenic Syndrome by a licensed physician. * Patients must be able to provide informed consent, or have a guardian who does. * Patient must be able to travel to the site of treatment. Exclusion Criteria: * Patients will be excluded from the trial if they are pregnant or have active cancer (malignancy) at the screening consultation.
Interventions
- BiologicalAlloEx exosomes
This is an intranasal treatment of exosomes derived from mesenchymal stem cells.
Locations (3)
- Prodromos Stem Cell InstituteNaples, Florida
- Prodromos Stem Cell InstituteIrving, Texas
- Medical Surgical Associates CenterSt John's